Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Retained Earnings data on file, last reported at -$430.0 million in Q1 2026.

• Quarterly Retained Earnings fell 191845.54% year-over-year to -$430.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$430.0 million (down 191845.54% YoY) and the FY2025 annual result came in at -$339000.0, down 212.25% from the prior year.
• Retained Earnings retreated to -$430.0 million in Q1 2026, from -$416.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $302000.0 in Q3 2024 to a low of -$430.0 million in Q1 2026.
• A 5-year average of -$106.2 million and a median of -$3.0 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2024 — Retained Earnings jumped 125.72% — and 2025, when it sank 1437372.41%.
• Tracing ENTA's Retained Earnings over 5 years: stood at -$2.7 million in 2022, then tumbled by 8886.99% to -$240.4 million in 2023, then surged by 99.99% to -$29000.0 in 2024, then slumped by 1437372.41% to -$416.9 million in 2025, then fell by 3.14% to -$430.0 million in 2026.
• The last three Retained Earnings figures came in at -$430.0 million (Q1 2026), -$416.9 million (Q4 2025), and -$339000.0 (Q3 2025), per Business Quant data.